Peter Attia· MD
I think they came in with an average LDL cholesterol of 74 milligrams per deciliter and in a very short period of time you know something to the neighborhood of two and a half years saw an amazing event risk reduction
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
I think they came in with an average LDL cholesterol of 74 milligrams per deciliter and in a very short period of time you know something to the neighborhood of two and a half years saw an amazing event risk reduction
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
and in post-doc analyses of these trials you can see that the benefit was also correlated with the uh reduction in ldl levels so patients that have the lowest ldl levels had the lowest uh risk of having a second event
earlier exposure to evalacabab to exposure to a lower LDL has a legacy effect with continued lower risk of events